Amgen Will Launch First US Eylea Biosimilar At Risk

First US Aflibercept Is On The Way After Amgen Dodges Another Attempt At Injunction

 
• By Dean Rudge

A watershed moment is on the horizon for US biosimilars, with Amgen looking poised to debut competition to Eylea (aflibercept).

Businessman showing risk level indicator rating since low to high for risk management and assessment review concept
• Source: Shutterstock

More from Biosimilars

More from Legal & IP